CME Information
Provider Statement: This continuing medical education activity is provided by 
.
Support Statement: This activity is supported, in part, by an educational grant from Celgene Corporation.
Target Audience: The intended audience for the activity is oncologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
Learning Objectives: Upon successful completion of this activity, participants should be better able to:
- Incorporate appropriate biomarkers to aid in clinical decision-making for patients with NSCLC.
- Utilize the latest clinical evidence regarding the use of new or emerging targeted agents and immune checkpoint inhibitors in selecting therapies for patients with NSCLC.
- Review the clinical evidence regarding options, combinations, and sequencing following first-line immune checkpoint inhibitor therapy.
- Evaluate recently approved and emerging treatment options in the context of standard of care for patients with SCLC.
- Apply the latest clinical evidence regarding the use of immune checkpoint inhibitors for patients with SCLC, including those with extensive disease.
- Review clinical considerations regarding combinations and sequencing.
Activity Chair:
Carlos Becerra, MD
Medical Oncologist
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Dallas, TX
Faculty:
Edward S. Kim, MD
Chair, Department of Solid Tumor Oncology and Investigational Therapeutics
Levine Cancer Institute
Atrium Health
Charlotte, NC
Patrick A. Ott, MD, PhD
Clinical Director of the Center for Immuno-Oncology and Melanoma Center
Associate Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Accreditation:
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, February 27, 2020, through February 26, 2021.
How to Participate in This Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of the 3 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.
The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.
Activity Chair and Faculty report the following relationship(s):
Carlos Becerra, MD
Consulting Fee: Agenus, Bayer, Heron Therapeutics, Ipsen, Sobi, Takeda
Speakers Bureau: Bristol-Myers Squibb, Celgene, Taiho Pharmaceutical
Edward S. Kim, MD, FACP
Consulting Fee: AstraZeneca, Boehringer Ingelheim, Merck, Pfizer, Roche, Takeda
Patrick A. Ott, MD, PhD
Consulting Fee: Array BioPharma, Novartis, Roche/Genentech
Contracted Research: ARMO BioSciences, Bristol-Myers Squibb, Celldex, CytomX, Medimmune/AstraZeneca, Merck, Neon Therapeutics, Pfizer, Roche/Genentech
Reviewer reports the following relationship(s):
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at cme@vindicoCME.com